Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Base Year
Historical Year
Forecast Year
The global cancer cachexia market size attained a value of USD 2.32 billion in 2023 driven by continuous clinical trials in oncology, expanding mindfulness among individuals and healthcare experts, presence of an enormous pool of undiscovered patients, quick urbanisation, and expanding government support for healthcare. The market is anticipated to grow at a CAGR of 4.7% during the forecast period of 2024-2032 to attain a value of USD 3.51 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The global market for cancer cachexia is expected to be driven by rising instances of cachexia and developments in modern treatment systems. North America, Europe and Japan are expected to be key markets. Cases of cachexia are growing and presently, the condition affects nearly 1 percent of all patients. Recent years have witnessed increased understanding of the multifarious nature of cachexia, in particular, the function of inflammatory mediators and anabolic and catabolic imbalances. While many treatment methodologies have not been able to clear phase III clinical trials despite initial promise, the ghrelin receptor agonist anamorelin has delivered initial results.
Cachexia is a serious outcome of a variety of chronic conditions, and associated with a poor quality of life. In last-stage chronic heart failure, the occurrence of cachexia ranges from 5–15 percent; in cases of advanced cancer, the incidence of cachexia lies between 50–80 percent. Many people with chronic renal disease, chronic obstructive pulmonary disease (COPD), and rheumatoid arthritis develop cachexia as they near the end of their lives. Cachectic syndrome is a key source of morbidity and mortality in cancer patients. Cancer cachexia has also been linked to decreased chemotherapeutic efficacy, increased adverse effects, and discontinuation of treatment. Progressive cachexia signals poor prognosis with a shorter survival time, and explains close to 20 percent of all cancer deaths. If there is weight loss of 10 percent or more within a period of 6 months, it may indicate presence of cachexia. There is a direct relation between survival of cancer patients and rate and amount of weight loss.
Cachectic syndrome is described to have three stages - precachexia, cachexia, and refractory cachexia. In the precachectic stage, indications such as such as weight loss (less than 5 percent), anorexia, and impaired glucose tolerance appear. Advancement to cachexia depends on several factors including systemic inflammation, type and stage of cancer, low food intake, and response to treatment. In refractory cachexia, active weight loss management is rendered almost impossible due to active catabolism or presence of cachectic factors. Patients experiencing acute muscle wasting are not likely to gain from treatments aimed at achieving lean tissue and function. In this phase, therapy seeks to mitigate symptoms and reduce distress rather than prolong life.
At present, cancer cachexia is incurable. Current therapies for cachexia entail a multidisciplinary approach; combination therapy including diet adjustments and exercise (where possible) has been integrated with new medicinal agents such as Megestrol acetate, medroxyprogesterone, ghrelin, and omega-3-fatty acid, among others. These treatments have been reported to yield better survival rates and quality of life. Advancements in treatment systems and promise shown by under-trial drugs are expected to boost the market.
In 2021, Helsinn, a Swiss pharmaceutical group engaged in the production of high-quality cancer care and rare disease products, announced the first launch of Adlumizo (anamorelin) to treat cancer cachexia in malignant non-small cell lung cancer, gastric cancer, pancreatic cancer and colorectal cancer in Japan, through Ono Pharmaceutical, its partner firm. Adlumizo (anamorelin), approved by the Japanese Health Authorities, has been shown to be effective in increasing body weight, muscle mass, and appetite in cancer cachexia patients.
AV-380 by AVEO is first-in-class, potent, humanized inhibitory IgG1 antibody targeting growth differentiation factor 15 (GDF15). Preclinical data suggest that inhibition of GDF15 leads to a switch from catabolism to anabolism, which indicates that GDF15 inhibition with AV-380 may reverse the effects of cachexia. As of 2023, AVEO Oncology completed enrolment in its phase I trial in Cachexia (In volunteers) in USA (Parenteral) (NCT04815551), and planned to commence a phase Ib trial in Cancer in mid-2022.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
By therapeutics, the market is divided into:
By mechanism of action, the market is classified into:
By distribution channel, the market is segmented into:
By region, the market is classified into:
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The report presents a detailed analysis of the following key players in the market, looking into their capacity, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
The EMR report gives an in-depth insight into the industry by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.
REPORT FEATURES | DETAILS |
Base Year | 2023 |
Historical Period | 2017-2023 |
Forecast Period | 2024-2032 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Therapeutics |
|
Breakup by Mechanism of Action |
|
Breakup by Distribution Channel |
|
Breakup by Region |
|
Market Dynamics |
|
Supplier Landscape |
|
Companies Covered |
|
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
In 2023, the global market of Cancer Cachexia attained a value of USD 2.32 billion.
The market is anticipated to grow at a CAGR of 4.7% during the forecast period of 2024-2032 to reach a value of USD 3.51 billion by 2032.
The major drivers of the market include the neglected requirement for the therapy of cancer cachexia in creating economies, continuous clinical trials in oncology, expanding mindfulness among individuals and healthcare experts, presence of an enormous pool of undiscovered patients, quick urbanisation, and expanding government support for healthcare.
The rising instances of cachexia and developments in modern treatment systems are the key industry trends propelling the market's growth.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
On the basis of therapeutics, the market is divided into progestogens, corticosteroids, and combination therapy, among others.
Based on mechanism of action, the market is divided into appetite stimulators and weight loss stabilisers.
The several distribution channels include hospital pharmacy, retail pharmacy, and online pharmacy.
The major players in the industry are Merck & Co., Inc., Aphios Corporation, Helsinn Healthcare SA, AVEO Pharmaceuticals, Inc., Ono Pharmaceutical Co., Ltd., and Pfizer Inc., among others.
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share